Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma

Qian Xie,Hanrui Zheng,Ye Chen,Xingchen Peng

DOI: https://doi.org/10.3389/fpubh.2022.965798

IF: 5.2

2022-07-27

Frontiers in Public Health

Abstract:[This corrects the article DOI: 10.3389/fpubh.2022.837854.].

public, environmental & occupational health

What problem does this paper attempt to address?

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Ru Zhou,Mahboubeh Yazdanifar,Lopamudra Das Roy,Lynsey M. Whilding,Artemis Gavrill,John Maher,Pinku Mukherjee

DOI: https://doi.org/10.3389/fimmu.2020.628776

IF: 7.3

2020-12-07

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2019.01149.].

immunology
Corrigendum: Impact of Serum Uric Acid Lowering and Contemporary Uric Acid-Lowering Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.

Hangying Ying,Hongdi Yuan,Xiaomei Tang,Wenpu Guo,Ruhong Jiang,Chenyang Jiang

DOI: https://doi.org/10.3389/fcvm.2021.723626

IF: 3.6

2021-01-01

Frontiers in Cardiovascular Medicine

Abstract:[This corrects the article DOI: 10.3389/fcvm.2021.641062.].
Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma

Qian Xie,Hanrui Zheng,Ye Chen,Xingchen Peng

DOI: https://doi.org/10.3389/fpubh.2022.837854

IF: 5.2

2022-04-28

Frontiers in Public Health

Abstract:Objective: Avelumab (MSB0010718C) is a fully human anti-programmed cell death ligand 1(PD-L1) antibody against PD-L1 interactions and enhances immune activation against tumor cells in the meantime. Avelumab has been approved for locally advanced or metastatic urothelial cancer (mUC) after disease progression in several countries. We therefore conducted this study to evaluate the cost-effectiveness of avelumab maintenance therapy for advanced or mUC from the perspective of the United States (US) and China payer. Methods: A Markov simulation model was performed based on clinical trial JAVELIN Bladder 100. Utilities and costs adopted in this analysis were derived from published literature and clinical trials. Incremental cost-effectiveness ratios (ICERs) were calculated to compare the avelumab maintenance therapy group (AVE group) and the best supportive care group (CON group). Results: The ICER of the AVE group compared with the CON group were 16,150.29 per QALYs in the overall population and in the PD-L1–positive population, respectively. While the ICER of AVE group compared with CON group were 100,528.29 per QALYs in the overall population and in the PD-L1–positive population, respectively. Conclusion: Avelumab maintenance therapy was a cost-effective first-line treatment compared with BSC in patients with mUC which were not progressed with platinum-based chemotherapy not only in the PD-L1–positive population but also in the overall population based on the current willingness to pay (WTP) of 30,447.09 in China.

public, environmental & occupational health
Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Wen-Jie Wu,Qian Liu,Pu-Gen An,Lin Wang,Jian-Yun Zhang,Yan Chen,Tong Zhang,Jie Zhang

DOI: https://doi.org/10.3389/fimmu.2023.1346845

IF: 7.3

2024-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1282629.].
Palliative Gastrectomy Plus Chemotherapy versus Chemotherapy Alone for Incurable Advanced Gastric Cancer: A Meta-Analysis [Corrigendum]

Pei Wu,Pengliang Wang,Bin Ma,Songcheng Yin,Yuen Tan,Wenbin Hou,Zhenning Wang,Huimian Xu,Zhi Zhu

DOI: https://doi.org/10.2147/cmar.s455833

2024-01-01

Cancer Management and Research

Abstract:[This corrects the article DOI: 10.2147/CMAR.S179368.].

oncology
Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Bi-Cheng Wang,Bo-Ya Xiao,Peng-Cheng Li,Bo-Hua Kuang,Wang-Bing Chen,Pin-Dong Li,Guo-He Lin,Quentin Liu

DOI: https://doi.org/10.1155/2021/3735726

IF: 4.501

2021-02-25

Journal of Oncology

Abstract:[This corrects the article DOI: 10.1155/2020/2368164.].

oncology
Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan,Zhongzheng Zhu,Wei Mao,Hui Wang,Hong Qian,Jianguo Wu,Xianling Guo,Qing Xu

DOI: https://doi.org/10.3389/fonc.2021.796625

IF: 4.7

2022-01-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.683502.].

oncology
Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis

Yin Yang,Jianyang Wang,Wenqing Wang,Tao Zhang,Jingjing Zhao,Yu Wang,Yexiong Li,Luhua Wang,Nan Bi

DOI: https://doi.org/10.3389/fonc.2022.1007862

IF: 4.7

2022-08-24

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.810580.].

oncology
Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Xuan Wei,Juanjuan Shi,Qianhan Lin,Xiaoxue Ma,Yingxin Pang,Hongluan Mao,Rui Li,Wei Lu,Yu Wang,Peishu Liu

DOI: https://doi.org/10.3389/fonc.2021.742374

IF: 4.7

2021-09-07

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.642229.].

oncology
Corrigendum: Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies

Jun Cao,Mengdi Zhang,Bin Wang,Long Zhang,Fangfang Zhou,Meiyu Fang

DOI: https://doi.org/10.3389/fonc.2021.745052

IF: 4.7

2021-08-17

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.658552.].

oncology
Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”

TingAn Wang,HuaGe Zhong,YuZhou Qin,WeiYuan Wei,Zhao Li,MingWei Huang,XiaoLing Luo

DOI: https://doi.org/10.1155/2021/3179693

2021-02-09

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2020/3575038.].

biotechnology & applied microbiology,medicine, research & experimental
[Corrigendum] PF‐2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells

Chen Chen,Dinghua Yang,Qinghua Zeng,Liang Luo,Chengzhi Cai

DOI: https://doi.org/10.3892/etm.2024.12399

IF: 2.7

2024-01-24

Experimental and Therapeutic Medicine

Abstract:[This corrects the article DOI: 10.3892/etm.2018.5967.].

medicine, research & experimental
Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors

Francesca Arezzo,Gaia Giannone,Daniele Castaldo,Giulia Scotto,Valentina Tuninetti,Margherita Turinetto,Michele Bartoletti,Serafina Mammoliti,Grazia Artioli,Giorgia Mangili,Vanda Salutari,Domenica Lorusso,Gennaro Cormio,Vera Loizzi,Claudio Zamagni,Antonella Savarese,Massimo Di Maio,Graziana Ronzino,Carmela Pisano,Sandro Pignata,Giorgio Valabrega

DOI: https://doi.org/10.3389/fonc.2023.1357793

IF: 4.7

2024-01-22

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2023.1247291.].

oncology
Different Patient Subgroup Different Maintenance, Proteasome Inhibitors Or Immunomodulators Maintenance For Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data In China (Vol 11, 665217, 2021)

Xiaoyan Han,Chunxiang Jin,Gaofeng Zheng,Donghua He,Yi Zhao,Yi Li,Wenjun Wu,Weiyan Zheng,Guoqing Wei,Enfan Zhang,He Huang,Jingsong He,Zhen Cai

DOI: https://doi.org/10.3389/fonc.2021.740715

IF: 4.7

2021-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.665217.].
Corrigendum: Autophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/β-Catenin/ABCG2 Axis

Mianmian Liao,Caiwei Wang,Bowen Yang,Danping Huang,Yifeng Zheng,Shengqi Wang,Xuan Wang,Juping Zhang,Chunbian Tang,Zheng Xu,Yu He,Ruolin Huang,Fengxue Zhang,Zhiyu Wang,Neng Wang

DOI: https://doi.org/10.3389/fphar.2022.809565

IF: 5.6

2022-02-15

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2021.659297.].

pharmacology & pharmacy
Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial

Fengrui Xu,Yang Zhang,Zhanhui Miao,Xiaohua Zeng,Biao Wu,Li Cai,Jinping Liu,Shusen Wang,Xichun Hu,Wenbo Zheng,Zhiyue Chen,Qing Yang,Zefei Jiang

DOI: https://doi.org/10.21037/atm-2020-23

IF: 3.616

2020-05-01

Annals of Translational Medicine

Abstract:[This corrects the article DOI: 10.21037/atm.2019.07.95.].

oncology,medicine, research & experimental
Corrigendum: A novel Chinese herbal and corresponding chemical formula for cancer treatment by targeting tumor maintenance, progression, and metastasis

Ying-Chyi Song,Der-Yen Lee,Pei-Yen Yeh

DOI: https://doi.org/10.3389/fphar.2023.1312683

2023-11-24

Abstract:[This corrects the article DOI: 10.3389/fphar.2022.907826.].
Corrigendum: Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: a systematic review and meta-analysis

Cong-wen Yang,Ru-dong Chen,Qing-run Zhu,Shi-jie Han,Ming-jie Kuang

DOI: https://doi.org/10.3389/fimmu.2023.1344990

IF: 7.3

2024-01-04

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.923286.].

immunology
Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Qitong Chen,Dengjie Ouyang,Munawar Anwar,Ning Xie,Shouman Wang,Peizhi Fan,Liyuan Qian,Gannong Chen,Enxiang Zhou,Lei Guo,Xiaowen Gu,Boni Ding,Xiaohong Yang,Liping Liu,Chao Deng,Zhi Xiao,Jing Li,Yunqi Wang,Shan Zeng,Jinhui Hu,Wei Zhou,Bo Qiu,Zhongming Wang,Jie Weng,Mingwen Liu,Yi Li,Tiegang Tang,Jianguo Wang,Hui Zhang,Bin Dai,Wuping Tang,Tao Wu,Maoliang Xiao,Xiantao Li,Hailong Liu,Lai Li,Wenjun Yi,Quchang Ouyang

DOI: https://doi.org/10.3389/fonc.2021.661128

IF: 4.7

2021-03-05

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.00811.].

oncology
Corrigendum: Quercetin Induces Apoptosis Via Downregulation of VEGF/Akt Signaling Pathway in Acute Myeloid Leukemia Cells

Huan Shi,Xin-Yu LI,Yao Chen,Xing Zhang,Yong Wu,Zi-Xuan Wang,Pan-Hong Chen,Hui-Qi Dai,Ji Feng,Sayantan Chatterjee,Zhong-Jie Li,Xiao-Wei Huang,Hong-Qiao Wei,Jigang Wang,Guo-Dong Lu,Jing Zhou

DOI: https://doi.org/10.3389/fphar.2020.640750

IF: 5.6

2021-02-08

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2020.534171.].

pharmacology & pharmacy

Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Corrigendum: Impact of Serum Uric Acid Lowering and Contemporary Uric Acid-Lowering Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.

Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma

Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Palliative Gastrectomy Plus Chemotherapy versus Chemotherapy Alone for Incurable Advanced Gastric Cancer: A Meta-Analysis [Corrigendum]

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis

Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Corrigendum: Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies

Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”

[Corrigendum] PF‐2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells

Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors

Different Patient Subgroup Different Maintenance, Proteasome Inhibitors Or Immunomodulators Maintenance For Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data In China (Vol 11, 665217, 2021)

Corrigendum: Autophagy Blockade by Ai Du Qing Formula Promotes Chemosensitivity of Breast Cancer Stem Cells Via GRP78/β-Catenin/ABCG2 Axis

Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial

Corrigendum: A novel Chinese herbal and corresponding chemical formula for cancer treatment by targeting tumor maintenance, progression, and metastasis

Corrigendum: Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: a systematic review and meta-analysis

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Corrigendum: Quercetin Induces Apoptosis Via Downregulation of VEGF/Akt Signaling Pathway in Acute Myeloid Leukemia Cells